Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease

Haematologica

Volumn 98, Issue 3, 2013, Pages 371-375

  Marinelli, Marilisa ^a   Peragine, Nadia ^a   Di Maio, Valeria ^a   Chiaretti, Sabina ^a   De Propris, Maria Stefania ^a   Raponi, Sara ^a   Tavolaro, Simona ^a   Mauro, Francesca Romana ^a   Del Giudice, Ilaria ^a   Guarini, Anna ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; INCIDENCE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PROTEIN FUNCTION; RADIOSENSITIVITY; UPREGULATION; WESTERN BLOTTING; CANCER STAGING; EXON; GENETICS; METABOLISM; MUTATION; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; EXONS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874532132     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.069906     Document Type: Article

References (15)

1. Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589-97.
2. Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322-9.
3. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91(11): 4342-9.
4. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009;23(1):117-24.
5. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995-1004.
6. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, et al. ERIC recommendations on TP53 mutation analysis in Chronic Lymphocytic Leukemia. Leukemia. 2012;26 (7):1458-61.
7. Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23 (1):212-4.
8. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009; 114(5):957-64.
9. Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M, et al. Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia. J Clin Oncol. 2011; 29(19):2703-8.
10. Ehrlich M, Zhang XY, Inamdar N. Spontaneous deamination of cytosine and 5-methylcytosine residues in DNA and replacement of 5-methylcytosine residues with cytosine residues. Mutat Res. 1990; 238(3):277-86.
11. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science. 1990;249(4972):970-1.
12. Chiaretti S, Tavolaro S, Marinelli M, Messina M, Del Giudice I, Mauro FR, et al. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer. 2011; 50(4):263-74.
13. Guarini A, Marinelli M, Tavolaro S, Bellacchio E, Magliozzi M, Chiaretti S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica. 2012; 97(1):47-55.
14. Rossi D, Gaidano G. ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter. Haematologica. 2012;97(1):5-8.
15. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98(3):814-22.